Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Liminatus Pharma Inc's Competitiveness

Name: Liminatus Pharma Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Liminatus Pharma Inc (LIMN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/LIMN/competitors                    

                        https://api.csimarket.com/api/v1/companies/LIMN/relationships                    

                        https://api.csimarket.com/api/v1/companies/LIMN/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Liminatus Pharma Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Liminatus Pharma Inc	-	-	-	Yes
High-Confidence Competitors (8)
Similar-Size Competitors (9)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

LIMN Stock Performance relative to its Competitors

LIMN Competitors (weighted) Percent change over the selected range

Liminatus Pharma Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(5 of 6)

Similar-Size
(0 of 8)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Liminatus Pharma Inc	195.90 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (6)	40.4%	63.2%
Similar-Size Competitors (8)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Liminatus Pharma Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

LIMN Stock Performance relative to High-Confidence Competitors

LIMN High-Confidence Competitors (equal-weighted, 9) Percent change over the selected range

LIMN Stock Performance relative to Similar-Size Competitors

LIMN Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Liminatus Pharma Inc's Comment on Competition and Industry Peers

The company operates in the immune-oncology treatment sector and faces competition from pharmaceutical and biotechnology firms including Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Merck, Novartis, Pfizer, Roche, and Roche's subsidiary Genentech. These competitors may also offer opportunities for combination therapies. In the area of CD47-targeting drug candidates, Magrolimab, developed by Forty Seven (acquired by Gilead Sciences), is a notable competitor currently in Phase 3 clinical trials for cancer treatment.

Competitor data is not yet available for Liminatus Pharma Inc.

Liminatus Pharma Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
BMS	Named by the company	85%	2022 to 2026	3
Novartis	Named by the company	85%	2022 to 2026	3
Amgen	Named by the company	85%	2022 to 2026	3
Gilead Sciences	Named by the company	85%	2022 to 2026	3
Forty Seven	Named by the company	85%	2022 to 2026	3
Pfizer	Named by the company	85%	2022 to 2026	3
AstraZeneca	Named by the company	85%	2022 to 2026	3
Merck	Named by the company	85%	2022 to 2026	3
Genentech	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Liminatus Pharma Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.